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Abstract: Membrane microdomains or lipid/membrane rafts are distinct areas on the plasma membranes, where a specific 
subset of lipids (e.g. cholesterol, sphingolipids) and proteins (e.g. glycosylphosphatidylinositol-anchored proteins, growth 
factor receptor/kinases) are getting together and functioning for several aspects of cellular functions. Our recent investiga-
tion has revealed that fertilization of African clawed frog, Xenopus laevis, requires cholesterol-dependent nature of egg 
membrane microdomains. Moreover, fertilization of Xenopus eggs involves proteolytic cleavage of the extracellular part 
and subsequent phosphorylation of a cytoplasmic tyrosine residue of uroplakin III, an egg membrane microdomain-
associated protein. Protease activity toward uroplakin III seems to be derived from fertilizing sperm, while phosphoryla-
tion of uroplakin III seems to be catalyzed by the egg tyrosine kinase Src, whose activation is required for cytoplasmic re-
arrangement of fertilized eggs; so-called ‘egg activation’. Therefore, it is assumed that uroplakin III serves an integral part 
of signal transduction in fertilization of Xenopus. Our more recent study on human cancer cells has revealed that a similar 
but distinct scheme of signal transduction operates in anti-apoptotic growth of cells. Namely, in human bladder carcinoma 
cells, cooperation of uroplakin III and Src, both of which localize to the membrane microdomains, allows cells to escape 
from apoptotic cell death and proliferate under culture conditions deprived of serum. In this review, I briefly introduce 
about biology of fertilization and cancer, and then present and discuss our experimental data on general importance and 
specific features of membrane microdomains in Xenopus fertilization and anti-apoptosis in human bladder carcinoma 
cells. 
SIGNAL TRANSDUCTION OF FERTILIZATION 
Overview of Fertilization Research 
  Fertilization is the union of two gamete cells; egg and 
sperm that combines two paternally prepared genetic materi-
als and that gives rise to a newborn with a distinct genetic 
background to their parents [1-7]. Although recent advances 
in biotechnology (i.e. somatic cell nuclear transfer) has en-
abled us to create cloned animals in some species including 
mammals [7], whose genetic materials are practically as 
same as their donor animals, there has been no exception in 
that fertilization is the only mean for natural offspring in 
sexual reproduction system. Therefore, to understand mo-
lecular and cellular mechanism of fertilization has been a 
long-thought theme in biology and medicine, by which we 
may establish more effective strategies for medical and 
pharmaceutical treatments, for agricultural and industrial 
productions, for taking care of environmental issues, and 
most of all, for understanding of ourselves, human being. 
Fertilization, by its terminology, cover several successive 
aspects of reproduction; including gametogenesis (oogene-
sis/spermatogenesis and acquisition of ability to be fertil-
ized), gamete interaction with reproductive tract (especially 
in mammals) and with each other, gamete fusion, activation 
of egg/oocytes, and establishment and initiation of zygotic  
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development (including implantation in mammals). Practi-
cally, however, the research field of fertilization covers more 
deeply inside from sperm-egg interaction through initiation 
of development than other processes. In this view, the fol-
lowing three questions have been asked as general and major 
questions in the fertilization field. How does sperm (or egg) 
recognize and interact with egg (or sperm)? [1-4] How do 
sperm and eggs fuse with each other? [8,9] How does fertil-
ized egg get activated to initiate embryonic development? 
[10-13]  
How do Sperm and Egg Interact and Fuse with Each 
Other? 
  A number of studies have been conducted to answer 
aforementioned questions by using several model organisms. 
Not only vertebrates like mammals, birds, reptiles, amphib-
ian, and fishes, but also invertebrates such as insects, nema-
todes, and sea creatures have been employed. Fig. (1) depicts 
current state of our knowledge on a sequence of events asso-
ciated with fertilization, in other words, signal transduction 
of fertilization, by highlighting four organisms analyzed ex-
tensively; sea urchin, frog, newt, and mouse. At present, 
sperm-egg interaction at the plasma membrane level is most 
uncertain subject. Biochemical and immunochemical studies 
in the mouse have identified some candidates for sperm-egg 
membrane interaction; for instance, a disintegrin and metal-
loproteinase or ADAMs in sperm and integrins in eggs 
[14,15]. However, genetic deletion of these molecules by 
gene knockout could not eliminate the ability of eggs or 
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molecules are not essential for this process [16-18]. Until 
now, no gene knockout experiments have succeeded in ob-
taining phenotype that sperm-egg interaction is impaired. On 
the other hand, the same experimental approach has identi-
fied two gene products, egg CD9 [19-21] and sperm Izumo 
[8,9,22], as essential components for sperm-egg membrane 
fusion in mouse. CD9 is a member of tetraspanin molecules 
that contain four transmembrane domains as well as two 
extracellular loops and two cytoplasmic sequences. It is also 
known that CD9 constitutes a protein complex with certain 
kinds of integrin, a cell adhesion protein, and serves as 
membrane organizer [23-27]. Recent reports have demon-
strated that fragments of egg membranes containing CD9 are 
transferred to sperm surface, by which sperm may acquire 
the ability to fertilize egg [28]. It should also be noted that 
sperm surface also express functional integrin complexes 
that seem to be important for sperm-egg interaction and fu-
sion [29]. Izumo processes an immunoglobulin-like domain 
in its extracellular sequence [22], which has been implicated 
in molecular interaction in several other immunoglobulin-
like domain-containing proteins. Both CD9 and Izumo pro-
teins, however, do not possess intrinsic activity for mem-
brane fusion like SNARE complex. Therefore, it seems that 
these two proteins act to orchestrates structural assembly 
and/or function of membrane-associated molecules directly 
involved in fusion process.  
Membrane Events Leading to Egg Activation at Fertili-
zation  
  Gene knockout approach is not yet available in other spe-
cies presented in Fig. (1). Instead, much larger number as 
well as size (or volume) of eggs that can be obtained from 
one animal has enabled researchers to conduct more detailed 
biochemical and cell biological experiments. It is noteworthy 
that adult, female mouse would give us ~10 eggs with a di-
ameter of ~200 m per ovulation, while adult, female frog 
would give us ~1000 eggs with a diameter of ~1300 m per 
ovulation. In sea urchin, sperm post-acrosomal protein 
bindin [30] and egg EBR1 [31,32] have been identified and 
characterized as components for species-specific interaction 
of gametes at the egg vitelline membrane level, although its 
relationship to gamete fusion and egg activation is unclear. 
In Xenopus, a sperm protein containing disintegrin sequence, 
named xMDC16 [33,34], has been suggested to be a compo-
nent to interact with and activate egg. Synthetic peptides 
containing disintegrin motifs, such as Lys-Thr-Cys [34], 
which is present in the xMDC molecule, and Arg-Gly-Asp 
[35], which has not yet been identified in any of Xenopus 
sperm proteins, has been shown to activate Xenopus eggs, 
suggesting the presence of functional integrin(s) on egg sur-
face. Several types of integrin (heterodimer of  and  
subunits) have been identified in Xenopus  [36]; however, 
their involvement in sperm-egg interaction and egg activa-
tion has not yet been demonstrated. Another candidate 
mechanism for sperm-egg interaction in Xenopus involves 
proteolysis [37]. External application of protease such as 
cathepsin B promotes egg activation in Xenopus, suggesting 
that sperm-derived cathepsin B-like protease, if present, is 
involved in gamete interaction and egg activation. In support 
with this, specific inhibitors for cathepsin B inhibits not only 
cathepsin B-induced egg activation but also sperm-induced 
egg activation. As a candidate for protease substrate on the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Signal transduction leading to Ca
2+ transient at fertilization in sea urchin, Xenopus laevis (frog), Cynops pyrrhogaster (newt), and 
mouse. Shown schematically is sequence of events at fertilization in four model organisms (sea urchin as representative of sea invertebrates, 
frog and newt as representative of amphibian vertebrates, and mouse as representative of mammalian vertebrates). In all species, IP3-
dependent mechanism is a dominant component of intracellular Ca
2+ release (as highlighted in red), which is necessary for successful egg 
activation by sperm. In most species, molecular detail of sperm-egg membrane interaction and fusion is unknown and may be varied between 
species (as highlighted in green). Special note that genetic approach has identified sperm Izumo and egg CD9 as essential components for 
sperm-egg fusion. Egg cytoplasmic events connecting sperm-egg interaction/fusion and IP3-dependent Ca
2+ release are semi-conserved 
among species and involve tyrosine kinase-dependent or -independent actions of PLCs (as highlighted in yellow). 
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egg surface, a single transmembrane protein uroplakin III has 
been identified [38, for detail see below]. One question 
arises as to whether such protease-substrate interaction is 
sufficient for cellular interaction done by egg and sperm. 
Association of uroplakin III with egg membrane microdo-
mains and its possible functions in sperm-egg interaction and 
egg activation will be discussed later. Molecular detail of 
sperm-egg fusion in Xenopus is, as in case of sea urchin, not 
well understood. The fact that CD9, an egg molecule that is 
essential for sperm-egg fusion in the mouse, is also present 
in Xenopus eggs [39] would allow researchers to evaluate the 
function of this molecule in the near future. In summary, 
mechanisms of sperm-egg interaction and fusion seems to be 
quite different among model organisms and its understand-
ing at molecular level awaits further investigation. 
Mechanism of Ca
2+ Transient at Fertilization  
  The term “egg activation” means a sum of biological 
events that culminates in activation of embryonic develop-
ment. It includes resumption of the egg’s cell cycle (from the 
metaphase of meiosis II in most mammals and amphibians), 
block to polyspermy, fusion of female and male nuclei, and 
synthesis of zygotic genome DNA [2,4,6,40]. Cytoplasmic 
events leading to egg activation have been analyzed exten-
sively in many animal species, and it is well established that 
transient rise of intracellular Ca
2+ concentration, in short 
Ca
2+ transient, plays a universal role in executing egg activa-
tion [2,4-6,41]. In other words, egg activation is dependent 
on the occurrence of Ca
2+ transient. In support of this, artifi-
cial elevation of intracellular Ca
2+ concentration can repro-
duce essentially all events of egg activation. Upstream 
events of Ca
2+ transient are also conserved among species; at 
least in four organisms shown in Fig. (1), phospholipase C-
dependent production of inositol 1,4,5-trisphosphate (IP3) 
act to trigger Ca
2+ transient, which will initiate and propagate 
from the endoplasmic reticulum (Fig. 1). Thus, it is interest-
ing to note that, compared to diverse nature of membrane 
events of fertilization, cytoplasmic mechanism of fertiliza-
tion are highly conserved among species. Phospholipase C 
(PLC) is a family of enzymes that comprises of six subspe-
cies: , , , , , and   [42,43]. Among them are PLC and 
PLC, whose involvement in sperm-induced IP3 production 
and Ca
2+ transient has been demonstrated. In sea urchin and 
Xenopus, tyrosine phosphorylation of PLC, which is cata-
lyzed by Src family tyrosine kinases, is reported to be impor-
tant for egg activation [12,44]. Src-PLC pathway is well 
known to operate in several somatic cell systems such as T-
and B-lymphocytes, where cell surface receptors activate this 
pathway in response to binding to antigenic ligands [45-47]. 
In analogy of this, it is believed that sea urchin and Xenopus 
may utilize sperm-egg membrane interaction to promote 
signal transduction pathways leading to egg activation, as 
discussed in detail later. On the other hand, in the mouse, 
sperm-derived PLC has been shown to be involved in initi-
ating egg activation [13,48-51]. In this case, sperm-egg fu-
sion, which allows sperm to deliver its constituents: not only 
genetic materials but also other components including PLC, 
seems to be a critical for initiating egg activation. Thus, up-
stream events of IP3 production and Ca
2+ transient are semi-
conservative among species, in which sperm-egg membrane 
interaction or fusion acts as an initiator of signal transduction 
pathways leading to activation of PLCs (Fig. 1). It should be 
noted that, in the newt Cynops pyrrhogaster, another mecha-
nism of Ca
2+ transient has been show to operate. It involves 
sperm-egg membrane fusion and introduction of sperm-
derived citrate synthase (Fig. 1) [52]. Molecular mechanism 
by which citrate synthase induces Ca
2+ transient (tyrosine 
kinase? PLC? IP3?) remains to be clarified.  
MEMBRANE MICRODOMAINS AND FERTILIZA-
TION SIGNALING IN XENOPUS 
Overview of Membrane Microdomains or “Rafts” 
  The term “membrane microdomains” or “membrane/lipid 
rafts” denotes a distinct area or micro-segment on the plasma 
membranes, where a specific subset of proteins and mem-
brane lipids are getting together and working for certain cel-
lular functions [53-59]. It is sometimes called as “cavelolae 
microdomains” or more simply “caveolae”, when it involves 
invaginated membrane structures containing caveolin, a 
membrane-spanning protein [56]. With experimental basis, 
membrane microdomains are also called as “detergent-
insoluble membrane (DIM)” or “detergent-resistant mem-
branes (DRM)” [53,57,58]. Such detergent-insoluble or -
resistant nature of membrane microdomains is due to an en-
richment of cholesterol and saturated fatty acids that consti-
tute liquid-ordered membranes. Conventional preparation of 
membrane microdomains involves extraction of cell samples 
with Triton-X-100 (or other non-ionic detergents)-containing 
buffer at low temperature, followed by fractionation of the 
extracts with discontinuous sucrose gradient ultracentrifuga-
tion (Fig. 2A). The resulting fractions containing low-
density, detergent-insoluble materials are collected as mem-
brane microdomains. For further details of technical issues 
and merits of focused approach on egg membrane microdo-
mains in fertilization study, please refer to other literatures 
[60,61].  
Characterization of Membrane Microdomains of 
Xenopus Eggs 
  As discussed earlier, quality amounts of eggs in Xenopus 
system has allowed us to perform biochemical characteriza-
tion of signal transduction pathways leading to egg activa-
tion at fertilization. Earlier works in our laboratory have 
demonstrated that sequential activation of tyrosine kinase 
Src and PLC are required for IP3 production and Ca
2+ tran-
sient in fertilized Xenopus eggs [62-65]. Subsequent studies 
focusing on egg membrane microdomains have demon-
strated the following: Conventional preparation of membrane 
microdomains (see above) has allowed us to obtain low-
density, detergent-insoluble membrane fractions that are 
enriched in cholesterol, ganglioside GM1, and cytoplasmic 
tyrosine kinase Src [39], all of which are known membrane 
microdomain markers in many types of mammalian somatic 
cells. Fertilization promotes a rapid activation of membrane 
microdomain-associated Src, as judged by immunoblotting 
with use of phospho-tyrosine 416-specific antibody that rec-
ognizes activated Src molecules [39]. Fertilization also pro-
motes a transient recruitment of PLC to membrane micro-
domains, by which it is tyrosine-phosphorylated and acti-
vated by Src [65,66]. Application of methyl--cyclodextrin, 
a cholesterol-binding substance that disrupts organization of 
membrane microdomains, abolishes the activation of Src and 
subsequent egg activation events in fertilized eggs. Impor-
tantly, localization of Src and PLC to membrane microdo-52    The Open Biochemistry Journal, 2008, Volume 2  Ken-Ichi Sato 
mains is distorted methyl--cyclodextrin-treated eggs 
[39,66]. These results focusing on in vivo situations of mem-
brane microdomains (Fig. 2A) suggest that at least the cyto-
plasmic face of egg membrane microdomains acts as a struc-
tural platform for Src-dependent egg activation signaling at 
fertilization. Our next experiments evaluating function of 
extracellular face of egg membrane microdomains have 
demonstrated the following: 
Focused Proteomics on Xenopus Egg Membrane Micro-
domains  
  Egg membrane microdomains isolated from unfertilized 
eggs have been shown to contain functional Src protein. Sur-
prisingly, addition of sperm to this membrane microdomain 
preparation promotes activation of Src in vitro [66], indicat-
ing that sperm-interacting machinery, if any, may be func-
tionally preserved in this preparation and that it could be 
useful for in vitro reconstitution of sperm-egg membrane 
interaction and subsequent signal transduction. With these 
assumptions, we have performed several biochemical and 
cell biological experiments examining the ability of isolated 
membrane microdomains to reproduce fertilization events. In 
combination with cell-free extracts prepared form unfertil-
ized  Xenopus eggs (so-called cytostatic factor-arrested or 
CSF extract), sperm-treated membrane microdomain could 
reproduce Ca
2+ transient and subsequent egg activation proc-
esses that include resumption of meiotic cell cycle (as judged 
by the occurrence of morphological change of added sperm 
nuclei) and dephosphorylation of mitogen-activated protein 
kinase, an abundant protein serine/threonine kinase that 
regulates cell cycle of unfertilized eggs and early embryos in 
Xenopus [60,66]. Importantly, pharmacological inhibition or 
immunochemical depletion of Src or PLC shows an inhibi-
tory effect on all of these reconstituted fertilization events. 
Thus, membrane microdomains prepared from Xenopus eggs 
have allowed us to perform to some extent in vitro reconsti-
tution of signaling events at fertilization (Fig. 2A). 
Uroplakin III, a Novel Component of Fertilization  
  Focused proteomics approach on egg membrane micro-
domains has also gained a new insight for signal transduc-
tion at fertilization. Immunoblotting of egg membrane mi-
crodomain fractions with anti-phosphotyrosine antibody has 
demonstrated that a 30-kDa protein becomes tyrosine-
phosphorylated in fertilized eggs (5 min after insemination). 
Mass spectrometry analysis has demonstrated that it is uro-
plakin III (UPIII) [67]. UPIII is a member of uroplakin fam-
ily that consists of four members: UPIa and UPIb, both of 
which are tetraspanin molecules, and UPII and UPIII, both 
of which are single-transmembrane proteins [68,69]. UP 
family proteins are originally identified in bladder and kid-
ney tissues of mammals. They have been implicated in or-
ganizing rigid nature of apical surface of urothelial mem-
brane structures, which involves urothelial plaque containing 
UPIa/UPII and UPIb/UPIII heterogeneous protein com-
plexes. In addition, UP family proteins have been implicated 
in urinary bladder carcinomas, and some renal and infectious 
diseases [69-73]. Before our discovery of UPIII in Xenopus 
eggs, however, no information has been available as to the 
function of UP family proteins in reproduction and early 
development. Molecular identification of UPIII as a pre-
dominantly tyrosine-phosphorylated protein in the mem-
brane microdomains of fertilized eggs has led us to investi-
gate its physiological importance of this protein. Several 
biochemical and molecular biological studies have demon-
strated the following: 
Signal Transduction Involving Uroplakin III and Src in 
Xenopus Fertilization  
  UPIII localizes predominantly to the egg membrane mi-
crodomains before and after fertilization [67]. Exposure of 
the amino-terminal domain of UPIII on the egg surface has 
been confirmed by the fact that UPIII is effectively labeled 
by surface biotinylation of unfertilized Xenopus eggs [67]. 
The fact that fertilization promotes phosphorylation of UPIII 
on tyrosine-249, which locates in the cytoplasmic sequence 
of this protein (as determined by de novo sequencing with 
mass spectrometry), suggests that the egg cytoplasmic tyro-
sine kinase Src, which is also concentrated in membrane 
microdomains and activated upon fertilization (see above), 
catalyzes this phosphorylation. In support with this, a phar-
macological Src inhibitor PP2 abolishes tyrosine phosphory-
lation of UPIII. Another supporting evidence is that co-
expression of UPIII and Src in 293 human embryonic kidney 
cells results in effective tyrosine phosphorylation of UPIII 
[67,74]. Although physiological role of phosphorylation of 
the UPIII tyrosine-249 is currently unknown, it could be a 
specific binding site for certain phosphotyrosine-binding 
protein(s). One interesting candidate is PLC, which is re-
cruited to membrane microdomains in fertilized eggs (see 
above), because this protein contains two Src homology 2 
domains that can bind to certain phosphotyrosine-containing 
sequence. On the other hand, physiological importance of the 
extracellular domain of UPIII has been suggested by the fact 
that a specific antibody against the extracellular domain of 
UPIII shows an inhibitory effect on fertilization in a dose-
dependent manner [67]. The results obtained with anti-UPIII 
antibody suggest that the extracellular domain of UPIII is 
required for sperm-egg interaction and/or fusion at fertiliza-
tion. 
Uroplakin III is a Candidate Target for Sperm-Derived 
Protease  
  UPIII has been identified as a target of sperm-derived 
protease, which has an enzymatic property similar to cathep-
sin B and is essential for fertilization [38]. The antibody 
against the extracellular domain of UPIII seems to abolish 
the proteolytic action of sperm. A synthetic peptide that cor-
responds to a potential proteolytic site in UPIII (containing 
Gly-Arg-Arg sequence, a proteolytic motif for cathepsin B) 
has been shown to block proteolysis of UPIII by sperm pro-
tease in vitro and fertilization in vivo [38]. Although these 
results do not exclude the possibility that other cell surface 
molecules could also be an important substrate for sperm-
derived protease, it is possible to surmise that UPIII is a part 
of protein complex for interacting with fertilizing sperm. In 
293-cell expression system, UPIII requires UPIb for its 
proper localization to the membrane microdomains [72,74]. 
Co-expression of UPIb, UPIII and Src results in inactivation 
of Src, as judged by elimination of phosphorylation of tyro-
sine-416, as well as by decrease of tyrosine phosphorylation 
of other cellular proteins [74]. Thus, it is attractive to specu-
late that in the membrane microdomains of unfertilized eggs, 
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that upon fertilization, proteolytic cleavage of UPIII some-
how releases the active form of Src inside the egg, thereby 
Src undergoes phosphorylation of important substrates such 
as UPIII and PLC (Fig. 2B).  
Future Directions of the Research  
  Focused proteomics approach on membrane microdo-
mains has also been conducted in sea urchin egg and sperm, 
and mammalian sperm [75-80]. In particular, sperm mem-
brane microdomains are under extensive investigation with a 
focus on the roles of glycosphingolipids and other carbohy-
drates [79,80]. Further study, in combination with molecular 
biological approach, will be necessary to evaluate the 
physiological function of membrane microdomains in fertili-
zation. In this sense, relationship of membrane microdo-
mains and sperm-egg fusion system in the mouse (i.e. 
CD9/Izumo system) will be of quite interest. 
ANTI-APOPTOTIC GROWTH OF CANCER CELLS 
Overview of Biological Functions of Cancer Cells  
  Understanding of biological functions of cancer cells is 
of universal importance and prerequisite for establishing 
effective strategy for prevention, diagnosis, treatment and 
prognosis of cancer. Since our grasp of cancer as a result of 
aberrant action of several gene products that regulate normal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Study of fertilization signaling focusing on structure and function of egg plasma membrane microdomains. (A) Schematic drawing 
of preparation of membrane microdomains from Xenopus eggs, which are unfertilized, fertilized, or artificially activated (parthenogenetically 
activated), and its utility in functional analysis. (B) Schematic diagram showing a series of events that operates during early phase of fertili-
zation of Xenopus eggs. Sperm-induced egg activation may involve proteolytic cleavage of the egg membrane microdomain-associated uro-
plakin III, catalyzed by sperm-derived protease. Uroplakin III is in association with uroplakin Ib, a tetraspanin molecule that supports the 
localization of uroplakin III to membrane microdomains. The uroplakin III-uroplakin Ib complex is involved in negative regulation of cyto-
plasmic tyrosine kinase Src, and proteolytic cleavage of uroplakin III may lead to up-regulation of Src by unknown mechanism. Activated 
Src phosphorylates and activates PLC, which in turn promotes IP3 production and Ca
2+ transient. Src may also phosphorylate intact uro-
plakin III, although its physiological importance has not yet been demonstrated. 54    The Open Biochemistry Journal, 2008, Volume 2  Ken-Ichi Sato 
cellular function, much effort has been made to characterize 
cellular functions peculiar to cancer cells and its molecular 
basis [81,82]. Apoptosis is a cellular mechanism that main-
tains a balance of various cellular functions through the ac-
tive elimination of unnecessary cells from the living organ-
ism [83,84]. Its appropriate execution is important for proper 
animal development, namely early embryogenesis, later 
morphogenesis and body-shape-making. In adult, apoptosis 
is still important for balancing homeostasis and, as high-
lighted in this review, for preventing growth of aberrantly 
proliferating or malignantly transformed cells. All of normal 
cells, with an important exception in germ cells, will die ac-
cording to their pre-programmed longevity, in other words, 
aging and senescence, in which proper arrangement of chro-
mosomes will be distorted [85,86]. Even before the longev-
ity, cells exposed to serious damages that include the expo-
sure to ultraviolet, radioactivity, medicines etc. undergo cell 
death by apoptosis or necrosis, another style of cell death 
involving passive or unpredicted processes. In general, can-
cer cells arise from a summation of mutations occurred on 
some genes that are critically important for normal cell pro-
liferation and/or cell death [81,82]. It means that cancer cells 
acquire not only the ability to proliferate aggressively but 
also the ability to escape from being killed by themselves 
(anti-apoptosis) or by other reasons (anti-longevity or anti-
necrotic cell death). With an emphasis on anti-apoptotic 
mechanism of cancer cell function, our studies on human 
cancer cells have demonstrated the following: 
Analysis of Bladder Carcinoma Cells Focusing on its Re-
sistance to Apoptosis  
  There are several experimental conditions that promote 
apoptosis in cultured cancer cells. They include application 
of Fas ligand, a death inducer, or anti-Fas antibody, hypoxia, 
hydrogen peroxide, irradiation, and chemical inhibitors for 
metabolic enzymes or signaling pathways etc. [87-89]. Se-
rum starvation serves as one of such pro-apoptotic cellular 
conditions examined to date. At the initial stage of carcino-
genesis, cancer cells are not necessarily surrounded by capil-
lary system. Under such microenvironment, however, cancer 
cells can proliferate effectively; thereby they are capable of 
inducing angiogenesis that will help cancer cells to populate 
more and to undergo invasion and metastasis (Fig. 3). We 
have employed human bladder carcinoma cell line 5637 as a 
model cell system to analyze molecular mechanism of serum 
starvation-resistant growth of cancer cells [90-92]. Survival 
and growth of this cell line in serum-free conditions have 
been reported to involve the actions of ligands for epidermal 
growth factor receptor/kinase (EGFR/kinase) [93], suggest-
ing that protein tyrosine phosphorylation plays a central part 
of survival signaling. In support of this, immunoblotting with 
anti-phosphotyrosine antibody has demonstrated that a num-
ber of proteins become tyrosine-phosphorylated in response 
to serum starvation [94]. Interestingly, time course of in-
crease in tyrosine phosphorylation is quite slow; about eight 
hours are required for its plateau phase, indicating that up-
regulation of EGFR/kinase ligands, if any, may need some 
hours to be promoted. Immunoprecipitation studies have 
demonstrated that 170-kDa EGFR/kinase is tyrosine-
phosphorylated in serum-starved 5637 cells; however, it is 
different from a more prominently tyrosine-phosphorylated 
protein of 145 kDa. Mass spectrometric analysis has demon-
strated that it is -subunit of hepatocyte growth factor recep-
tor/kinase (HGFR/kinase or c-Met). Although HGFR/kinase 
and its cognate high affinity ligand HGF/scatter factor (SF) 
have been originally identified in liver cells (hepatocytes), 
they are ubiquitously expressed in many kinds of cells and 
tissues, and implicated in a number of cellular functions 
(growth, differentiation, apoptosis etc.) [95,96]. Therefore, it 
is possible to think that, in addition to EGFR/kinase and its 
ligands, HGFR/kinase and HGF/SF are involved in the sur-
vival mechanism of 5637 cells under serum-free conditions. 
Mechanism of Anti-Apoptotic Function in Bladder Car-
cinoma Cells  
  Consistently with the previous findings by others that 
neutralizing antibodies to EGFR/kinase could abolish the 
growth of 5637 cells under serum-free conditions, a chemi-
cal inhibitor for EGFR/kinase (AG99) shows an inhibitory 
effect on growth of serum-starved 5637 cells. However, nei-
ther a potent inhibitor for HGFR/kinase (K252a [97]) nor a 
neutralizing substance for HGF/SF (Cu
2+ ions [98]) showed 
such an inhibitory effect. Among other pharmacological 
kinase inhibitors challenged, Src-specific inhibitors (PP2 and 
SU6656 [99-101]) were most inhibitory to cell growth in 
serum-starved 5637 cells. Moreover, both EGFR/kinase in-
 
 
 
 
 
 
 
 
 
Fig. (3). Initiation, promotion and progression of carcinogenesis: from benign tumor to malignant tumor. (A) Survival and growth under 
microenvironment where no supply of energy and nutrient is available. Serum starvation in cell culture may mimic such a microenvironment 
in vitro. (B) Anti-apoptotic mechanism of cancer cells. Cell become invasive and enter newly formed capillary (induction of angiogenesis). 
(C) Newly formed capillary supports growth and survival of tumor. Cells travel through bloodstream and undergo metastasis. This scheme is 
adapted from “The Bi9ology of Cancer” by R.A. Weinberg (Garland Science, 2007). 
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hibitors and Src inhibitors (but not HGFR/kinase inhibitor) 
were shown to block effectively tyrosine phosphorylation of 
the 145-kDa c-Met protein (hereafter p145
met). Therefore, we 
conclude that tyrosine phosphorylation of p145
met is not due 
to autophosphorylation of the kinase, but rather due to trans-
phosphorylation events catalyzed by EGFR/kinase and/or 
Src family kinases [94]. In some cancer cells (such as breast 
cancer), coordinate action of EGFR/kinase and Src has been 
shown to be required for their malignant phenotype [102-
104]. So, our further study has focused on the roles of these 
two kinases in the molecular mechanism of survival in se-
rum-starved 5637 cells.  
Tyrosine Phosphorylation-Dependent Mechanism of 
Anti-Apoptosis  
  Inhibition of cell growth in serum-starved 5637 cells in 
the presence of PP2 involves apoptosis, because concomitant 
increase of cell death and activation of caspase 3/7-like pro-
tease are observed [94]. Importantly, PP2 does not show 
such an effect on 5637 cells cultured in serum-containing 
conditions, suggesting that Src activity is specifically re-
quired for viability of 5637 cells under serum-free condi-
tions. On the other hand, AG99 shows a growth-inhibitory 
effect in both culture conditions, indicating that 
EGFR/kinase activity is required for both culture conditions. 
In 5637 cells, at least three types of Src family kinases are 
expressed; Src, Yes, and Fyn. Among them are Src and Yes 
that are activated in response to serum starvation [94]. Ex-
pression of kinase-negative Src also promotes apoptotic cell 
death in 5637 cells only under serum-free conditions (manu-
script in preparation). Taken together, we conclude that Src 
activity is required for anti-apoptotic growth of 5637 cells 
under serum-free conditions. Further biochemical characteri-
zation of anti-apoptotic growth of serum-starved 5637 cells 
have demonstrated the following: 
Signal Transduction Leading to Anti-Apoptosis Involves 
MT1-MMP and HB-EGF  
  Among several ligands for EGFR/kinase [93] are hepa-
rin-binding EGF-like growth factor (HB-EGF [105,106]) 
that may serve as a main component to trigger EGFR/kinase 
activation in response to serum starvation of the cells. This is 
demonstrated by the facts that secretion of HB-EGF, but not 
EGF, into the culture medium is upregulated in serum-
starved cells and that a specific antibody to HB-EGF, but not 
that to EGF, promotes apoptosis of serum-starved 5637 cells 
(manuscript in preparation). GM6001 [107], a potent inhibi-
tor for matrix metalloproteinase (MMP) that is known to be 
an important regulator for secretion of HB-EGF and other 
EGFR/kinase ligands, also promotes apoptosis in serum-
starved 5637 cells (manuscript in preparation). Among sev-
eral kinds of MMPs is membrane type-1 MMP (MT1-MMP 
[108]) that may be involved in anti-apoptotic mechanism of 
serum-starved 5637 cells, because its protein expression is 
upregulated under serum-free culture conditions, and it be-
comes associated with Src and phosphorylated on tyrosine 
residues, which would act as an activating signal for MT1-
MMP [109]. Thus, signal transduction pathway for anti-
apoptotic growth of 5637 cells may involve expression of 
MT1-MMP by unknown mechanism, secretion of HB-EGF 
and its binding to EGFR/kinase, sequential activation of 
EGFR/kinase and Src, and phosphorylation of MT1-MMP 
(further activation of HB-EGF signal) and p145
met (down-
stream signaling for anti-apoptosis, see below) (Fig. 4A). 
Importance of p145
met in anti-apoptotic mechanism has been 
demonstrated as follows: 
p145
met is a Mediator of Anti-Apoptotic Function of 
Bladder Carcinoma Cells  
  The fact that a potent inhibitor for p145
met K252a does 
not inhibit phosphorylation of p145
met and growth 5637 cells 
[94] suggests that catalytic activity of p145
met is not required 
for anti-apoptotic function of 5637 cells. However, another 
evidence that apoptosis in serum-starved 5637 cells is pro-
moted by downregulation of p145
met by high concentrations 
of HGF [94], which causes endocytosis and breakdown of 
p145
met [110,111], indicates that the presence of tyrosine 
phosphorylated p145
met is required for anti-apoptotic mecha-
nism. Mass spectrometric analysis of p145
met prepared from 
serum-starved cells demonstrates that tyrosine residues 1003, 
1234, and 1235 are phosphorylated. Paradoxically, phos-
phorylation of tyrosine 1003 in p145
met has been shown to be 
important for the interaction with Cbl adaptor protein and 
subsequent ubiquitin-dependent degradation of the p145
met 
molecule [110]. Under this background, it will be interesting 
to examine expression of Cbl and -Pix. -Pix is an interact-
ing protein for the PAK protein serine/threonine kinase, 
which counteracts the action of Cbl-dependent downregula-
tion of receptor/kinases such as EGFR/kinase [112,113]. 
Thus, it is possible to think that in serum-starved 5637 cells, 
the expression level and/or functional level of -Pix is more 
dominating than that of Cbl, thereby allows the phosphoty-
rosine 1003-containing p145
met molecule to be survived on 
the plasma membranes.  
Possible Roles of Tyrosine Phosphorylation in p145
met : 
Speculations  
  On the other hand, phosphorylation of tyrosine residues 
1234 and 1235 may be important more directly to anti-
apoptotic mechanism. These phosphotyrosine residues are 
reportedly important for interaction with and activation of 
phosphatidylinositol 3-kinase (PI 3-kinase) [95, 114]. Acti-
vated PI 3-kinase is responsible for activation of ser-
ine/threonine kinase Akt that can phosphorylate and inacti-
vate BAD [115], a proapoptotic protein that upregulates re-
lease of cytochrome c oxidase from mitochondria [116]. As 
cytochrome c oxidase is known to be a positive regulator of 
caspase 9, which in turn activates a release of active forms of 
downstream caspases 3 and 7, the signal cascade involving 
p145
met-PI 3-kinase-Akt serves to act as anti-apoptotic 
mechanism. Phosphorylated p145
met may also recruit Grb2-
Sos complex that can activate Ras, a small GTP-binding pro-
tein. Ras is well known to act upstream regulators of mito-
gen-activated protein serine/threonine kinase (MAPK) cas-
cade [117]. Activated Ras-MAPK cascade has been shown 
to promote transcriptional activation of certain kind of genes 
such as Bcl-2 and Bcl-xL, both of which are anti-apoptosis 
components that act on the release of cytochrome c from 
mitochondria [118]. It is interesting to note that phosphoryla-
tion of BAD by the PI 3-kinase-Akt pathway is a relatively 
rapid, non-genomic process, whereas expression of Bcl-2 
and Bcl-xL is a relatively slow, genomic process. Consider-
ing the fact that signal transduction of anti-apoptotic growth 
in serum-starved cells requires several hours for execution 56    The Open Biochemistry Journal, 2008, Volume 2  Ken-Ichi Sato 
(e.g. ~8 hours for phosphorylation of p145
met, see above), 
complex mode of actions involving both non-genomic and 
genomic processes may contribute to anti-apoptotic mecha-
nisms in serum-starved 5637 cells. Future studies focusing 
on these pro-apoptotic and anti-apoptotic components, which 
would act downstream of p145
met, will clarify which compo-
nents are really functioning in this cancer cell system. 
MEMBRANE MICRODOMAINS AND ANTI-
APOPTOSIS 
Membrane Microdomains in Bladder Carcinoma Cells  
  All proteins so far identified to be important for anti-
apoptotic mechanism in 5637 cells have property to associate 
with plasma membranes (i.e. MT1-MMP, HB-EGF, 
EGFR/kinase, Src and p145
met). Therefore, like in Xenopus 
egg system discussed above, we have an interest to analyze 
the structure of membrane microdomains of 5637 cells and 
its physiological importance in anti-apoptotic growth under 
serum-free conditions. Under this background, we have 
found that methyl--cyclodextrin inhibits tyrosine phos-
phorylation of EGFR/kinase, Src and p145
met, and promotes 
apoptosis in serum-starved 5637 cells ([119], manuscript in 
preparation). The results strongly suggest that cholesterol-
dependent membrane microdomains play an important role 
in anti-apoptotic mechanism in serum-starved 5637 cells. As 
in the case of Xenopus eggs, membrane microdomains of 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Anti-apoptotic mechanism of survival and growth of serum-starved 5637 human bladder carcinoma cells. Serum starvation signal 
may trigger both non-genomic (e.g. catalytic and/or physical protein interactions) and genomic responses (gene expression and/or protein 
synthesis) in 5637 cells. At early phase of signal transduction, activation of Src by unknown mechanism, activation of MT1-MMP by tyro-
sine phosphorylation and/or increased protein expression, secretion of soluble HB-EGF into the culture medium, and proteolysis of uroplakin 
III are operating. Secreted HB-EGF binds to and activates EGFR/kinase. Src may also be activated under the control of EGFR. Src and 
EGFR phosphorylate -subunit of HGFR/c-Met (p145) on tyrosine residues 1003, 1234, and 1235. These phosphotyrosine residues in -
subunit of HGFR/c-Met may be responsible for up-regulating anti-apoptotic ability of cells through PI 3-kinase-Akt pathway and/or Grb2-
Sos-Ras-MAPK pathway: the former contributes to phosphorylation and inactivation of BAD, a pro-apoptotic component of Bcl-2 family, 
and the latter contributes to induction of Bcl-2 and Bcl-xL, both of which are anti-apoptotic components of Bcl-2 family. These components 
act positively or negatively on cytochrome c oxidase, which will be released from mitochondria upon mitochondria-mediated apoptosis in 
response to metabolically sensed death signals (i.e. serum starvation). Cytochrome c oxidase, if released, promotes sequential activation of 
caspase 9 and caspase 3/7, latter of which directly contributes to apoptotic cellular processes. Thus, serum-independent survival and growth 
of 5637 cells may involve suppression of pro-apoptotic pathway and/or activation of anti-apoptotic pathway.  Membrane Microdomain in Cancer and Reproduction  The Open Biochemistry Journal, 2008, Volume 2    57 
5637 cells could have been prepared by extraction of cells 
with Triton X-100-containing buffer followed by fractiona-
tion of the cell extract with discontinuous sucrose density 
gradient ultracentrifugation. The resulting Triton X-100-
insoluble, low-density fractions are analyzed for the presence 
and function (e.g. phosphorylation) of signaling molecules, 
in comparison with those in non-microdomain fractions that 
are collected as detergent-soluble, high-density fractions. 
Experiments with use of subcellular fractions have demon-
strated the following: 
Anti-Apoptosis Involves Cholesterol-Dependent Mem-
brane Microdomains  
  Both Src and p145
met localize permanently to the mem-
brane microdomains in 5637 cells, and undergo tyrosine 
phosphorylation in response to serum starvation. On the 
other hand, EGFR/kinase localizes to membrane microdo-
mains and becomes tyrosine-phosphorylated only after se-
rum starvation of cells. Interestingly, treatment of cells with 
methyl--cyclodextrin results in the disappearance of all of 
these proteins from the membrane microdomains (manu-
script in preparation). This is not due to protein degradation 
but rather due to re-localization to the non-microdomain 
fractions. Regardless of the presence of these proteins, how-
ever, tyrosine phosphorylation is almost completely blocked 
in methyl--cyclodextrin-treated cells [119]. These results 
suggest that not only protein assembly in membrane micro-
domains but also tyrosine kinase signaling are distorted by 
the disruption of cholesterol-dependent membrane architec-
ture. Inability of these membrane microdomain-associated 
molecules to undergo tyrosine phosphorylation may be be-
cause of the lack of functional access to MT1-MMP and/or 
HB-EGF, whose subcellular localization and sensitivity to 
methyl--cyclodextrin are currently unknown. 
Possible Role of Uroplakin III in Anti-Apoptosis  
  Analysis of membrane microdomains of 5637 cells has 
also demonstrated a new insight of anti-apoptotic growth of 
this cell line. By the use of a specific antibody against the 
extracellular domain of Xenopus UPIII (see above), we have 
found that a 45-kDa protein homologous to Xenopus UPIII is 
present in membrane microdomains of 5637 cells. Report-
edly, human UPIII migrates at 45-50 kDa on SDS-
polyacrylamide gel electrophoresis [70,72]. Treatment of the 
membrane microdomain fraction with N-glycosidase F re-
sults in a reduction of molecular size of the 45-kDa protein 
to about 30 kDa, which matches with the calculated size of 
the core protein of human UPIII. Therefore, we conclude that 
the 45-kDa protein is human UPIII (hereafter designated as 
p45UPIII). Functional relevance of p45UPIII in anti-
apoptotic growth of 5637 cells has been suggested by the 
following observations: Like UPIII in Xenopus eggs, 
p45UPIII localizes predominantly to membrane microdo-
mains in 5637 cells (unpublished results). Treatment of 5637 
cells with methyl--cyclodextrin causes a dissociation of 
p45UPIII from membrane microdomains, indicating that as 
in case of EGFR/kinase, Src and p145
met, the association of 
p45UPIII with membrane microdomains depends on its cho-
lesterol-enriched nature. Although a cytoplasmic tyrosine 
residue, which is phosphorylated in Xenopus egg fertilization 
(tyrosine 249 in Xenopus UPIII [67]), is conserved in 
p45UPIII (tyrosine 266 in p45UPIII [120]), it is not phos-
phorylated in serum-starved 5637 cells. On the other hand, it 
is demonstrated that serum starvation promotes partial prote-
olysis of p45UPIII in a time course that is similar to tyrosine 
phosphorylation of p145
met (it is evident at ~8 h of serum 
starvation) (unpublished results). Pharmacological charac-
terization of partial proteolysis of p45UPIII has demon-
strated that the proteolytic reaction can be blocked effec-
tively GM6001, a potent MMP inhibitor, and some other 
protease inhibitors such as leupeptin. Interestingly, however, 
a synthetic peptide, which contains a potential proteolytic 
site in Xenopus eggs (Gly-Arg-Arg sequence, see above 
[38]), does not inhibit the proteolysis of p45UPIII in serum-
starved 5637 cells. Considering that the amino acid sequence 
covered by the synthetic peptide is completely conserved in 
Xenopus and human UPIII, it is plausible to think that prote-
olysis of p45UPIII occurs in a different site(s) of the mole-
cule.  
Proteolysis of Uroplakin III in Serum-Starved Bladder 
Carcinoma Cells  
  Another evidence that a specific antibody against the 
extracellular domain of UPIII can block effectively the pro-
teolysis of p45UPIII strongly suggests that proteolysis of 
p45UPIII occurs, as in the case of Xenopus UPIII, in the ex-
tracellular part of the molecule. Importantly, GM6001 or 
antibody against the UPIII extracellular domain promotes 
apoptotic cell death in serum-starved 5637 cells (unpub-
lished results). These results raise the possibility that prote-
olysis of p45UPIII is required for anti-apoptotic mechanism 
in serum-starved 5637 cells. Furthermore, inhibitors for Src 
family kinases (PP2 and SU6656) also shows an inhibitory 
effect on proteolysis of p45UPIII, suggesting that Src activ-
ity acts on upstream event of proteolysis; and paradoxically, 
GM6001 has an inhibitory effect on activation of Src and 
tyrosine phosphorylation of p145
met  (unpublished results). 
Thus, it seems that coordinate and complex network involv-
ing proteolysis and tyrosine phosphorylation drives the anti-
apoptotic mechanism in 5637 cells. Further approach on 
membrane microdomains to identify other signaling mole-
cules (e.g. targets of proteolytic action, substrates of tyrosine 
kinases) as well as gene targeting approach by using knock-
down technique (e.g. knockdown of MT1-MMP, p45UPIII 
etc.) will be useful to understand the molecular basis of sens-
ing of serum-starved culture conditions, executing anti-
apoptotic mechanism, and survival and growth of human 
cancer cells. 
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